Sanofi reports profit increase

Article Abstract:

Sanofi S.A. of France posted net income for the first quarter of 1.51 billion Euros ($1.92 billion). Revenues were due to strong vaccine sales despite increased competition from generic drug companies. The pharmaceutical giant is still integrating costs from the Aventis merger.

Sanofi S.A., Company overview

---

Sanofi stands by sleeping pill's safety profile

Article Abstract:

Sanofi-Aventis S.A. of France has reviewed research and says it will stand by its sleeping medication "Ambien." There were renewed concerns about the side effect of somnambulism. The pharmaceutical giant said it has found no reason to change the safety profile of the drug.

Product information, Sedatives, Hypnotics and sedatives, Hypnotics

---

Plavix sales brighten Sanofi's view

Article Abstract:

Fourth-quarter net income for French pharmaceutical firm Sanofi-Aventis S.A. increased 31% to $1.09 bil, while full-year sales in the US reached $4.07 bil. The firm announced a positive forecast, due in part to Plavix, its best-selling drug.

Forecasts, trends, outlooks, Company business forecast/projection, Company forecasts, Financial report

Similar abstracts:

• Abstracts: Unilever reports 35% profit gain: sales rise 3.3%. Tesco widens its lead over rivals in the U.K. Cadbury posts 46% rise in net, sets plan to offset higher costs
• Abstracts: Swiss Re Reports 41% Profit Decline. Swiss Life profit increases 8.5 percent on cost-cutting. Swiss Re losses raise wider fears: subprime hit spurs worries about insurers' exposure to credit-market turmoil
• Abstracts: EU wants to regulate cellphone roaming rates. New EU Chief outlines agenda to spur growth. EU regulators suspend review of Microsoft-ContentGuard deal

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.